Testing a drug with liver artery treatment for liver-spread neuroendocrine cancer
Part of Cancer, Digestive system clinical trials.
This early-stage study tests a cancer drug called tirapazamine, given along with a liver artery procedure (embolization) to treat liver-dominant metastatic neuroendocrine tumors. It aims to find a safe dose and see whether the combination can better control tumor growth in the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have neuroendocrine tumor (NET) cancer that has spread mainly to the liver, with liver tumors growing
- Your liver tumors take up less than half of your total liver volume
- You may have had prior approved treatments, but you still need eligibility for the liver artery procedure
- You must be age 20+ with good day-to-day function (ECOG 0–1) and no major heart, lung, or kidney problems
- Your liver artery procedure must be suitable (TAE or TACE) and your portal vein must not be blocked
- Your blood counts and organ labs must be in safe ranges, and you need effective pregnancy prevention
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment using a targeted liver procedure plus an immune “checkpoint” medicine to slow cancer growth. It may help people with advanced liver cancer (HCC) or metastatic stomach cancer when standard treatments have not worked.
This trial studies different ways to place treatments inside the liver to control liver tumors when they can’t be removed with surgery or ablation. It may help certain people by improving how well the tumor is treated while keeping liver function safer.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial tests whether giving medicine directly into the liver blood vessels before surgery can improve survival for people with liver cancer that has a blockage (tumor in the portal vein). It compares this approach plus surgery versus surgery alone in a randomized study.
This trial tests a treatment called yttrium-90 radioembolization (tiny radioactive beads delivered to the liver) for people with liver cancer that has already been treated before. The goal is to see if it can help control the tumor when other treatments haven't been enough.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.